Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.22.2
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 27 Months Ended
Jul. 01, 2021
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2024
Disaggregation of Revenue [Line Items]                  
Total revenue   $ 1,033   $ 3,355 $ 2,206 $ 3,829      
Amount fully reserved         1,000 0      
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio                  
Disaggregation of Revenue [Line Items]                  
Proceeds from divestiture of businesses     $ 2,200            
Total receivable balance   1,900     1,900     $ 1,900  
Amount fully reserved   1,000     1,000        
Remaining receivable balance   900     900     $ 900  
Forecast | Discontinued Operations, Disposed of by Sale | Pediatric Portfolio                  
Disaggregation of Revenue [Line Items]                  
Proceeds from divestiture of businesses             $ 2,000   $ 1,000
Product Revenue                  
Disaggregation of Revenue [Line Items]                  
Total revenue   1,033   $ 2,730 2,206 $ 3,204      
Millipred | Teva                  
Disaggregation of Revenue [Line Items]                  
Percent of net profit for installment payments               50.00%  
Installment payment $ 500                
Royalty expense   $ 400     $ 1,000        
Sales Revenue | Customer Concentration Risk | Major Customer Number One                  
Disaggregation of Revenue [Line Items]                  
Concentration risk percentage   86.00%     79.00%        
Sales Revenue | Customer Concentration Risk | Major Customer Number Two                  
Disaggregation of Revenue [Line Items]                  
Concentration risk percentage   14.00%     21.00%